Quality Improvement for Institutions
www.cvquality.acc.org

D2B Header Caps

Advertisement

AnticoagEvaluator App

The updated AnticoagEvaluator helps clinicians make informed decisions on antithrombotic therapy for their non-valvular AF patients.

Use the app to:

  • Calculate a patient's stroke risk (CHA2DS2-Vasc), bleed risk (HAS-BLED and concomitant meds), and renal function (Cockroft-Gault Equation)
  • Review stroke prevention therapy guidance based on ACC/AHA/HRS's 2014 Guidelines for the Management of Patients with Atrial Fibrillation
  • Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics
  • Determine appropriate therapy for a patient by reviewing
    • Synthesized individualized risk for antithrombotic therapy options based on clinical trials (e.g., ACTIVE-A, RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE-AF)
    • Relevant safety information and full prescribing information for all therapy options

The app is available on both iTunes (iPhones, iPads) and Google Play (Galaxy, Nexus, other Android devices). Use the links below from your mobile device to download the app.

The app is available for free.

  • Access on the web here.
  • Use the links below from your mobile device to download the App.

iTunes

Google Play

We want to hear from you!
Help ACC continuously improve our mobile clinical apps.

Questions?
Learn more about the App by reviewing a list of frequently asked questions.

This app was developed as part of the ACC's Anticoagulation Initiative. Financial support for the app was provided by Daiichi Sankyo, Inc. All content was independently developed with no sponsor involvement.

 


    Temp Styles

    American College of Cardiology: 2400 N St. NW, Washington DC 20006